Home » Stocks » BioDelivery Sciences

BioDelivery Sciences International, Inc. (BDSI)

Stock Price: $5.07 USD 0.53 (11.67%)
Updated Aug 14, 2020 2:32 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 511.74M
Revenue (ttm) 136.80M
Net Income (ttm) 5.79M
Shares Out 100.93M
EPS (ttm) 0.06
PE Ratio 84.50
Forward PE 24.94
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $5.07
Previous Close $4.54
Change ($) 0.53
Change (%) 11.67%
Day's Open 4.60
Day's Range 4.58 - 5.45
Day's Volume 7,436,187
52-Week Range 2.85 - 7.21

More Stats

Market Cap 511.74M
Enterprise Value 499.00M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 100.93M
Float 87.81M
EPS (basic) 0.06
EPS (diluted) 0.06
FCF / Share 0.20
Dividend n/a
Dividend Yield n/a
Earnings Yield 1.18%
FCF Yield 3.99%
Payout Ratio n/a
Shares Short 3.59M
Short Ratio 5.84
Short % of Float 4.64%
Beta 0.72
PE Ratio 84.50
Forward PE 24.94
P/FCF Ratio 25.04
PS Ratio 3.74
PB Ratio 5.35
Revenue 136.80M
Operating Income 11.13M
Net Income 5.79M
Free Cash Flow 20.44M
Net Cash 12.74M
Net Cash / Share 0.13
Gross Margin 66.74%
Operating Margin 8.13%
Profit Margin 4.20%
FCF Margin 14.94%
ROA 5.83%
ROE 7.67%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 8
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$8.00*
(57.79% upside)
Low
7.00
Current: $5.07
High
9.00
Target: 8.00
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue11155.6461.9915.5548.2338.9411.3654.543.263.40
Revenue Growth100.2%-10.24%298.72%-67.77%23.85%242.94%-79.18%1571.57%-4.17%-
Gross Profit89.8039.8642.494.2940.1334.019.2752.631.512.57
Operating Income3.74-23.65-29.42-63.94-35.18-38.74-56.407.06-26.99-16.32
Net Income-15.31-33.875.29-67.14-37.67-54.22-57.391.65-23.33-13.03
Shares Outstanding83.2163.1755.3653.6852.3848.3637.9430.5528.3223.15
Earnings Per Share-0.18-0.730.09-1.25-0.72-1.12-1.510.05-0.82-0.56
Operating Cash Flow11.07-24.11-32.45-53.98-3.73-28.83-60.1012.19-23.27-11.68
Capital Expenditures-0.08-0.11-0.01-0.41-0.70-1.60-0.08-0.04-0.29-0.10
Free Cash Flow10.99-24.23-32.46-54.39-4.43-30.44-60.1812.15-23.56-11.79
Cash & Equivalents63.8943.8221.2032.0283.5670.4723.1863.1910.7518.21
Total Debt58.5751.6547.6629.2728.8811.7019.18---
Net Cash / Debt5.32-7.83-26.472.7554.6958.774.0063.1910.7518.21
Assets18310988.1051.7210388.8438.0175.7423.6533.58
Liabilities11378.7979.2269.3971.0834.4438.8225.9619.5223.79
Book Value69.7629.748.88-17.6731.7054.40-0.8149.784.129.79
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name BioDelivery Sciences International, Inc.
Country United States
Employees 178
CEO Jeffrey Allen Bailey

Stock Information

Ticker Symbol BDSI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BDSI

Description

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in opioid tolerant adult patients with cancer. The company also offers Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.